Full Story, Every View.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Heatwaves
Artificial Intelligence
Wrestling
Social Media
World Cup
Donald Trump
Immigration and Customs Enforcement
Immigration
WWE
Education
Basketball
Music
biotuesdays.com image

News from biotuesdays.com

Information about biotuesdays.com

Where is biotuesdays.com located?biotuesdays.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biotuesdays.com News

Recurrent Somatic Mutation and Progerin Expression in Early Vascular Aging of Chronic Kidney Disease

Recurrent Somatic Mutation and Progerin Expression in Early Vascular Aging of Chronic Kidney Disease

67% Center coverage: 3 sources
Early vascular aging plays a central role in chronic kidney disease (CKD), but its molecular causes remain unclear. Somatic mutations accumulate in various cells with age, yet their functional contribution to aging tissues is not well understood. Here we found progerin, the protein responsible for the premature aging disease Hutchinson–Gilford progeria syndrome, steadily recurring in vascular smooth muscle cells of patients with CKD. Notably, th…See the Story
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-Free HIV Therapeutic DNA Vaccine

PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-Free HIV Therapeutic DNA Vaccine

100% Center coverage: 1 sources
GOLDEN, Colo.--(BUSINESS WIRE)--Jun 19, 2025-See the Story
Intensive Bevacizumab Boosts Vision in Macular Degeneration
Innovation

Intensive Bevacizumab Boosts Vision in Macular Degeneration

Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real-world study from the Netherlands shows.See the Story

Transgene Completes Initial Screening in Phase II Part of TG4050 Vaccine Trial

Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of vaccine, TG4050.The post Transgene completes initial screening in Phase II part of TG4050 vaccine trial appeared first on Clinical Trials Arena.Cancer · MarylandSee the Story

Firefly uncovers powerful new method of measuring SCD, MCI, and dementia in Alzheimer’s disease - BioTuesdays

Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer’s disease. This breakthrough enables a scalable and accessible approach to promote earlier detection and intervention. In the study, while EEG/ERP and …DementiaRead Article

Avalo appoints Dr. Rita Jain to BOD - BioTuesdays

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Rita Jain, MD, to its board of directors (BOD). To this role, Dr. Jain, a rheumatologist, brings more than two decades of leadership in biopharmaceutical development, clinical strategy, and regulatory affairs—across multiple therapeutic areas, including immunology, inflammation, nephrology, and rare diseases. She most recently served as EVP and CMO at ChemoCentryx. “We are please…Maryland · MarylandRead Article

MAIA enters into agreement with Roche to investigate THIO with Tecentriq - BioTuesdays

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq), for the treatment of multiple hard-to-treat cancers. In a statement, Vlad Vitoc, MD, chairman and CEO of MAIA, commented, “In preclinical studies, at…Maryland · MarylandRead Article

Ekso Bionics’ Acceptance Into NVIDIA Connect Program Bears Early Fruit

Green Stock News for the New Green Economy.San Mateo, California · San MateoSee the Story

USPTO issues patent for Lipella’s diagnostic technology - BioTuesdays

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing protection for its diagnostic technology through 2045—subject to potential extensions. The patent covers a method, using MRI, to detect lesions (or permeability defects) in body cavities. “This method can potentially provide enhan…United States · United StatesRead Article

Launchit Solutions enhancing patient outcomes through strategic partnerships and advanced medical programs - BioTuesdays

Open the article to view the coverage from biotuesdays.comRead Article

Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC

The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.United States · United StatesSee the Story

Breaking News Topics Related to biotuesdays.com

Cancer icon

Cancer

United States icon

United States

Medical icon

Medical

Health icon

Health

Maryland icon

Maryland

Canada icon

Canada

Colorado icon

Colorado

California, United States icon

California, United States

News
For You
SearchBlindspotLocal